|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's range||0.00 - 0.00|
|Beta (5Y monthly)||1.28|
|PE ratio (TTM)||1.27|
|Earnings date||01 Feb 2023 - 06 Feb 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Investors remain optimistic about Abiomed (ABMD) due to strength in its Impella product line.
Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) recently made headlines by announcing it will acquire medical device company Abiomed for $16.6 billion in an all-cash transaction. The buyout offer was roughly a 50% premium to where shares of Abiomed traded at the time of the announcement, signaling Johnson & Johnson's desire to make the deal happen. Few companies have the financial firepower Johnson & Johnson has, so I'll break down the acquisition's financial impact and whether Abiomed will make its new parent company a better investment for long-term investors.
Why he believes Abiomed is worth a "shock and awe" price. How Abiomed will strengthen Johnson & Johnson's medical device portfolio. Also, Motley Fool host Alison Southwick and Motley Fool personal finance expert Robert Brokamp discuss how shortcuts can make you a smarter saver.